August 3, 2012 - Seattle, Wash.
LLS Washington/Alaska Chapter nominates KING 5 for National Media Award
For the past three years, local NBC affiliate KING 5 has produced local :15 and :30 PSA's to promote our Seattle and South Sound Light The Night Walks. KING 5 reached out to the local NFL team, the Seattle Seahawks, and the Seattle Sounders, our local MLS team, to partner on these PSA's.
Here is the PSA featuring Seahawk Marcus Trufant, local anchor Paul Silvi, and our own honoree, Cole Vukich: http://www.youtube.com/watch?v=obJ2S0KCu1E&feature=em-share_video_user. Teams provided well-known and well-liked athletes to compliment our featured honored hero and the station's sports anchor in the videos. These PSA's boosted our registration rates of new walkers, and made existing teams feel like they were part of something even bigger and more exciting than in past years.
In addition, KING 5's friends and family team has raised thousands of dollars over the past two years. Here is a recent blog post from their community blog (with wide and active readership) that features one of our honorees, Braydon Hutchison: http://www.king5.com/community/blogs/community/2012-Honored-Hero-Braydon-Hutchison-162364476.html.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
The Washington/Alaska Chapter of LLS, based in Seattle, raises funds through a myriad of unique special events as well as its Team In Training program. Dollars raised provide support to local patients and their families, education programs for health care providers and research funding for local cancer researchers. To learn more, visit www.LLS.org/wa or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Partnership Seeks to Accelerate Development of Innovative Therapies
Approval marks first oral therapy for MCL patients, and a new option for patients with unmet medical need
Anti-CD20-Interferon Alpha Fusion Protein is a promising therapy for NHL patients resistant to standard therapy